1、Pharma R&D Annual Review 2022 Navigating the Landscape Discover more at: Paper2IntroductionWelcome to Pharmaprojects 2022 review of trends in pharmaceutical R&D.For 30 years now,Ive been taking an annual look at the evolution of pharma R&D,and in this article Ill examine the state of play at the sta

2、rt of 2022.Well assess industry trends by examining the pipeline by company,therapeutic area,disease,target,and drug type,using data from Pharma Intelligences Pharmaprojects,part of the Citeline suite of products,which has been tracking global drug development since 1980.This report will be followed

3、 up by our annual supplement reviewing the New Active Substance launches for the year just passed.But here,we will be packing our suitcases and heading to the airport to embark on a journey which circumnavigates the pharma world,travelling through both familiar territories and off the beaten track,t

4、o discover the direction of travel of the industry as it resets its compass following a turbulent couple of years,which have been quite a journey to say the least.Regular readers of this report(which has been running since 1993 so is presented here in its thirtieth edition)will know that in recent y

5、ears,Ive threaded a different theme through each edition,to highlight points,to draw analogies,and to add a little local colour into what could otherwise be a rather lengthy voyage through the dreary suburbs of statistics,charts,and tables.Themes selected so far have included astronomy,movies,the na

6、tural world,music,food and drink,and,last year,science fiction.Last autumn,as,in the UK at least,everything seemed to be pretty much back to normal COVID-wise,I selected travel for the theme of the 2022 report,expecting that this year would be the one in which everything returned to standard and,acc